NCT02129647View on ClinicalTrials.gov

Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

February 5, 2019

Study Completion Date

February 5, 2019

Conditions
Neurofibromatosis Type 2Vestibular Schwannomas
Interventions
DRUG

Axitinib

Trial Locations (1)

10016

NYU Langone Medical Center, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT02129647 - Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas | Biotech Hunter | Biotech Hunter